Day Two of National Healthcare Security Administration Negotiations: Pace of Company Exits Slows, Innovative Oncology Drugs Take Center Stage

① The pace of entries today has notably accelerated compared to yesterday, while the pace of corporate exits has somewhat slowed; ② During the afternoon session, staff conducted roll calls for some of the attending companies, including Novartis, AbbVie, Kelun-Biotech, Sunshine Guojing, and Bristol-Myers Squibb; ③ Lukangsatumab, as the first domestically produced and the second globally approved TROP2 ADC drug, is one of the highly anticipated products in this year’s national negotiation.

cls.cnOct 31 19:56

Day Two of National Healthcare Negotiations: Oncology and Chronic Disease Drugs Take Center Stage as Intense Bargaining Heats Up for Eli Lilly and Co, Novo-Nordisk A/S, Junshi Biosciences, Kelun Botai, and Others

①A large number of foreign enterprises have appeared, with intense competition today in anti-cancer drugs and lipid-lowering medications; ②A representative from Kelun Botai has emerged, with its drug Lupkynis (lutikizumab) being a “key contender” in this year’s national negotiations.

cls.cnOct 31 15:14

Express News | Second afternoon of the 2025 National Healthcare Security Administration negotiations: Novartis, Merck, Novo-Nordisk A/S, Kelun-Biotech, and Hengrui Pharma participate.

BreakingsOct 31 14:13

HKEX Announcements Highlights | Lens Technology Reports Approximately 20% Increase in Profits for the First Three Quarters; New Oriental Announces $300 Million Share Repurchase Plan

①Lens Technology's profit in the first three quarters increased by approximately 20%. What is the scale? ②New Oriental announces a $300 million share repurchase plan. What are the details?

cls.cnOct 28 20:25

Xuanzhu Bio-B (02575.HK): NG-350A Granted Fast Track Designation by the U.S. FDA

Gelonghui, October 28th丨Xuanzhu Bio-B (02575.HK) announced that NG-350A, a product licensed from clinical-stage oncology company Akamis, has been granted Fast Track designation by the U.S. Food and Drug Administration ("FDA") for the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR). The Group holds exclusive rights to develop, manufacture, and commercialize the NG-350A product in Greater China.

Gelonghui FinanceOct 28 16:32

Xuanzhu Biotech's share price rose as the company presented Phase III clinical trial data on pyrotinib for breast cancer treatment at the ESMO Annual Congress.

Xuanzhu Biotech-B (02575) rose over 5% again. As of the time of writing, it was up 5.12%, trading at HKD 62.65, with a turnover of HKD 23.5573 million.

Zhitong FinanceOct 27 10:49